Posted by Michael Wonder on 08 Jun 2022
Another new month, another terminated NICE appraisal
8 June 2022 - This time it is not for a cancer medicine.
NICE is unable to make a recommendation on the use of anifrolumab (Saphnelo) for the treatment of patients with active autoantibody positive systemic lupus erythematosus.
This is because AstraZeneca did not provide an evidence submission.
